TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06158828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti thymocyte globulin
Description: rATG is administered intravenously over 6-18 hours for a total of 2 to 3 doses. The daily dose is based on body weight and lymphocyte count.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti thymocyte globulin
Description: rATG is administered intravenously over 6-18 hours for a total of 2 to 3 doses. The daily dose is based on body weight and lymphocyte count.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan is administered intravenously either Q6H or Q24H, with a recommended target Busulfan AUC of 70-90 mg\*h/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is administered intravenously at a dose of 40 mg/m\^2/dose once daily for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is administered intravenously at a dose of 40 mg/m\^2/dose once daily for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa is administered intravenously at a dose of 5 mg/kg/dose Q12H for 2 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa is administered intravenously at a dose of 5 mg/kg/dose Q12H for 2 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is administered intravenously at a dose of 70 mg/m\^2/dose once daily for 2 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft
Description: The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0. There is no maximum limit for CD34+ dose. A maximum dose of 1 x 10\^5/kg recipient weight of TCRαβ cells should not be exceeded in the final HPC product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft
Description: The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0. There is no maximum limit for CD34+ dose. A maximum dose of 1 x 10\^5/kg recipient weight of TCRαβ cells should not be exceeded in the final HPC product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: memory-like natural killer cells
Description: The ML NK cells (dose: max capped at 20 x 10\^6/kg recipient weight, minimum dose allowed is 0.5 x 10\^6/kg recipient weight) will be infused on Day +7.
Study: NCT04753268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight Program
Description: The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight, physical activity, and meals daily.
Study: NCT06285136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEC3-VEN
Description: Venetoclax in combination with decitabine (+-sorafenib) Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 800mg/d, d8-14 (only for FLT3/ITD mutation positive patients)
Study: NCT06158828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: memory-like natural killer cells
Description: The ML NK cells (dose: max capped at 20 x 10\^6/kg recipient weight, minimum dose allowed is 0.5 x 10\^6/kg recipient weight) will be infused on Day +7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 is administered subcutaneously at a dose of 1 million units/m\^2 on Days +7, +9, +11, +13, +15, +17, and +19 (7 doses total).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 is administered subcutaneously at a dose of 1 million units/m\^2 on Days +7, +9, +11, +13, +15, +17, and +19 (7 doses total).

Intervention type: DRUG
Group type: OTHER
Intervention: Plerixafor
Description: If suboptimal collection of stem cells is predicted, plerixafor may be administered at a dose of 0.24 mg/kg subcutaneous injection once (maximum 40mg/dose). For patients with renal impairment, plerixafor will be administered at a dose of 0.16 mg/kg subcutaneous injection (maximum 27 mg/day).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Granulocyte Colony-Stimulating Factor
Description: G-CSF will be administered at a dose of 10 mcg/kg/day for 5 days, or 6 days if two days of collection are needed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: After stem cells are collected by leukapheresis, in order to create the HPC product, the stem cells will be washed to remove platelets and the cell concentration will be adjusted per laboratory and CliniMACS technology recommendations. The cells are then labeled using the CliniMACS TCRαβ Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: After stem cells are collected by leukapheresis, in order to create the HPC product, the stem cells will be washed to remove platelets and the cell concentration will be adjusted per laboratory and CliniMACS technology recommendations. The cells are then labeled using the CliniMACS TCRαβ Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product.
Study: NCT04683328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTA01
Description: Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCTA01 Placebo
Description: The excipients of SCTA01
Study: NCT05998226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Antimicrobial stewardship Team (VAT)
Description: The VAT consists of at least a clinical microbiologist and a clinician from the NH. Ideally, a pharmacist will also attend. They conduct a weekly (digital) meeting for nine months to evaluate the antibiotic prescriptions of the clinician attending the VAT meeting, based on a standardized protocol according to the current national infection treatment guidelines.
Study: NCT05142839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-CD
Description: EUS-guided choledochoduodenostomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-GEA
Description: EUS-guided gastroenterostomy
Study: NCT05498454

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathworks Mindfulness (Health or Stress Arm)
Description: As for previous descriptions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathworks Mindfulness (Health or Stress Arm)
Description: As for previous descriptions
Study: NCT05350124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: vitamin C (200 mg) capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: vitamin C (200 mg) capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol
Description: vitamin E (400 IU) capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol
Description: vitamin E (400 IU) capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo one pill only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo one pill only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo two pills only
Study: NCT05073549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Antimicrobial Stewardship Program (ASP)
Description: The collaborative ASP interventions will be implemented from October 1st, 2021 to September 30th, 2023 in all participating NICUs.~The collaborative ASP interventions include two levels of interventions that will be delivered at the NICU level: the NICU-targeted ASP program and collaborative quality improvement interventions to facilitate implementation of the ASP.~The core elements of the NICU-targeted ASP program include the establishment of ú ASP leader and team, development of the facility-specific antibiotic guidelines, checklist-led audit and feedback, and staff education.~The collaborative quality improvement interventions include data feedback and benchmarking, a potential 'better practice' list on neonatal antibiotic use, implementation using Plan-Do-Study-Act cycles and collaborative learning.
Study: NCT04805047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and monitoring
Description: regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback
Study: NCT05158023

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Sterile solution for subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASLAN004
Description: Sterile solution for subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASLAN004
Description: Sterile solution for subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASLAN004
Description: Sterile solution for subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASLAN004
Description: Sterile solution for subcutaneous injection
Study: NCT06040047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation
Description: Contract relax technique for each neck motion for three repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive mobilization
Description: To restore normal joint play, postero-anterior passive joint mobilization of cervical spine segments and cervicothoracic junction in limited motion will be applied.
Study: NCT05209724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider supervision/ feedback
Description: Provider supervision/ feedback provided before and after walking sessions
Study: NCT05144685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTX-202
Description: Experimental Pscyhoeducation and Intervention App

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTX-000
Description: Other Pscyhoeducation App
Study: NCT06546423

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B/HPIV3/HMPV-PreF-A vaccine
Description: B/HPIV3/HMPV-PreF-A is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-PreF-A vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10\^6.7 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10\^5.6 PFU in a 0.2 mL volume.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B/HPIV3/HMPV-F-B365 vaccine
Description: B/HPIV3/HMPV-F-B365 is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-F-B365 vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10\^6.3 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10\^5.6 PFU in a 0.2 mL volume.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringer's Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It will be drawn up in a sterile syringe to a volume of 0.2 mL.
Study: NCT05431725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Description: The influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.15 μg hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride,disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Quadrivalent influenza virus vaccine
Description: The Control Quadrivalent influenza virus vaccines are manufactured by Sanofi and are purchased by Pontifical Catholic University of Chile.15μg HA of each of the four influenza strains in 0.5 mL of solution per injection.The routine of administration is intramuscular injection into deltoid region.
Study: NCT06479200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-guided mindfulness
Description: The VR-guided mindfulness intervention is a 6-week home-based program delivered through an Oculus Quest 3 (or equivalent) headset. Participants practice 10-15 minutes of guided mindfulness exercises daily in immersive virtual environments. The program includes various mindfulness techniques such as body scans, breath awareness, and loving-kindness meditation, designed to reduce stress and improve well-being.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham VR
Description: The sham VR intervention is a 6-week home-based program that involves viewing relaxing nature videos without any mindfulness content. Participants use the same VR headset as the experimental group and engage with the sham content for 10-15 minutes daily, matching the duration of the experimental intervention. This sham intervention controls for the effects of using VR technology and engaging in a relaxing activity.
Study: NCT06332300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebelimumab+Famitinib + FOLFIRI+Ariely
Description: Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy
Study: NCT05062837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatectomy Combined With Camrelizumab and Apatinib
Description: Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
Study: NCT06369857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectopexy
Description: Suspension of apical organs
Study: NCT05426161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Botulinum Toxin A (10 units per cm2 wound areal) will be injected subcutaneously around the wound (1-2 cm from wound edge) maximum 200 units at each injection time.The total dose of BoNTA is maximum 400 units. Patient will receive one or two treatments in total.
Study: NCT02154347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAD-1229

Intervention type: DRUG
Group type: OTHER
Intervention: KAD-1229

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Study: NCT06308185

Intervention type: OTHER
Intervention: observational study
Description: Observational retrospective study on infants with neonatal seizures
Study: NCT06431113

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® )
Description: treatment for 4 months and then cross over to the other therapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® )
Description: treatment for 4 months and then cross over to the other therapy
Study: NCT05040334

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 1: Antibiotic receiving group
Description: Group 1; receiving antibiotic prophylaxis; single dose of oral doxycycline (200 mg) tablet and metronidazole (500 mg) tablet 2 hours before the surgical evacuation Group B ;receiving placebo 2 hours before the surgical evacuation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Antibiotic receiving group
Description: Group 1; receiving antibiotic prophylaxis; single dose of oral doxycycline (200 mg) tablet and metronidazole (500 mg) tablet 2 hours before the surgical evacuation Group B ;receiving placebo 2 hours before the surgical evacuation
Study: NCT05391919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal technology (MT)
Description: Patients will receive a course of rehabilitation with multimodal correction using BOS-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, in moderate paresis of the upper limb, the neurointerface Exokist-3 with EEG registration will be used. The program for IS patients includes 15 sessions with the MT: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal technology (MT)
Description: Patients will receive a course of rehabilitation with multimodal correction using BOS-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, in moderate paresis of the upper limb, the neurointerface Exokist-3 with EEG registration will be used. The program for IS patients includes 15 sessions with the MT: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation (CR)
Description: The patients will recieve Conventional rehabilitation technology (physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients includes 15 sessions with the CR: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
Study: NCT05769920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141) Ophthalmic Solution
Description: Eye drop twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141) Ophthalmic Solution
Description: Eye drop twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141) Ophthalmic Solution
Description: Eye drop twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141) Ophthalmic Solution
Description: Eye drop twice daily
Study: NCT06283680

Intervention type: PROCEDURE
Intervention: Lung transplantation
Description: Three different groups will be investigated with respect to the effect of NRI, BMI and body fat, muscle ratio on functional capacity, lung capacity, exercise capacity index, all-cause mortality, post-transplant intensive care unit stay and survival time in end-stage lung patients on the lung transplant list.

Intervention type: PROCEDURE
Intervention: Lung transplantation
Description: Three different groups will be investigated with respect to the effect of NRI, BMI and body fat, muscle ratio on functional capacity, lung capacity, exercise capacity index, all-cause mortality, post-transplant intensive care unit stay and survival time in end-stage lung patients on the lung transplant list.

Intervention type: PROCEDURE
Intervention: Lung transplantation
Description: Three different groups will be investigated with respect to the effect of NRI, BMI and body fat, muscle ratio on functional capacity, lung capacity, exercise capacity index, all-cause mortality, post-transplant intensive care unit stay and survival time in end-stage lung patients on the lung transplant list.
Study: NCT04777656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phase1 : CDED/Modulen™IBD® + Maintenance therapy
Description: from D0 until M2: Phase 1 (2 months run-in phase with CDED protocol + maintenance therapy, with the exception of corticosteroid that have to be tapered and stopped until M2.)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Phase1 : CDED/Modulen™IBD® + Maintenance therapy
Description: from D0 until M2: Phase 1 (2 months run-in phase with CDED protocol + maintenance therapy, with the exception of corticosteroid that have to be tapered and stopped until M2.)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phase1 : CDED/Modulen™IBD® + Maintenance therapy
Description: from D0 until M2: Phase 1 (2 months run-in phase with CDED protocol + maintenance therapy, with the exception of corticosteroid that have to be tapered and stopped until M2.)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phase2 and 3 :
Description: from M2 until M4 CDED phase 2 (introduction of a selected number of additional food). From M4 until end of the study CDED phase 3 (enlargement of number of additional foods and allowance of some initially excluded foods).